Background: The aim of this study was to examine high-sensitivity troponin T and I (hsTnT and hsTnI) after a treadmill run under laboratory conditions and to find a possible connection with echocardiographic, laboratory and other assessed parameters.
Methods: Nineteen trained men underwent a standardized 2-hour-long treadmill run. Concentrations of hsTnT and hsTnI were assessed before the run, 60, 120 and 180 minutes after the start and 24 hours after the run. Changes in troponins were tested using non-parametric analysis of variance (ANOVA). The multiple linear regression model was used to find the explanatory variables for hsTnT and hsTnI changes. Values of troponins were evaluated using the 0h/1h algorithm.
Results: Changes in hsTnT and hsTnI levels were statistically significant (p<0.0001 and p<0.0001, respectively). In a multiple regression model (adjusted R: 0.60, p=0.005 for hsTnT and adjusted R: 0.60, p=0.005 for hsTnI), changes in both troponins can be explained by relative left wall thickness (LV), training volume, body temperature after the run and creatinine changes. According to the 0h/1h algorithm, none of the runners was evaluated as negative.
Conclusions: Relative LV wall thickness, creatinine changes, training volume and body temperature after the run can predict changes in hsTnT and hsTnI levels. When medical attention is needed after physical exercise, hsTn levels should be tested only when clinical suspicion and the patient's history indicate a high probability of myocardial damage.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6298465 | PMC |
| http://dx.doi.org/10.1515/jomb-2017-0055 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Association of Modifiable Lifestyle Risk Factors with High-Sensitivity Troponin T and I Concentrations and Clinical Outcomes.
Eur J Prev Cardiol
November 2024
Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Aims: We aimed to investigate the association between the burden of modifiable lifestyle risk factors (modLRF) with high-sensitivity cardiac troponins T and I (hsTnT/I) and clinical outcomes in a contemporary cohort.
Methods: Patients undergoing coronary angiography with available hsTnT/I concentrations and information about modLRF were included in the current single-centre study. The modLRF investigated were overweight, lack of physical activity, poor adherence to a Mediterranean diet and current smoking.
Cardiac Myosin Inhibition in Heart Failure With Normal and Supranormal Ejection Fraction: Primary Results of the EMBARK-HFpEF Trial.
JAMA Cardiol
September 2024
Division of Cardiology, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
Article Synopsis
- - Patients with heart failure and preserved ejection fraction (HFpEF) who have an ejection fraction of 60% or higher have limited treatment options, making the study of new treatments important.
- - The EMBARK-HFpEF trial tested a drug called mavacamten on 30 patients with symptomatic HFpEF over 26 weeks, measuring outcomes such as NTproBNP and troponin levels to evaluate efficacy and safety.
- - Results showed significant reductions in NTproBNP and troponin levels, indicating potential benefits of mavacamten for these patients, although biomarker levels returned toward baseline after the drug was stopped.
Evaluation of the analytical and clinical performance of a high-sensitivity troponin I point-of-care assay in the Mersey Acute Coronary Syndrome Rule Out Study (MACROS-2).
Clin Chem Lab Med
September 2024
Department of Cardiology, Liverpool University Hospital NHS Foundation Trust, Liverpool, UK.
Objectives: The objective of this study is to evaluate the analytical and diagnostic performance of a high-sensitivity point-of-care (POC) cardiac troponin I assay, the Quidel TriageTrue™ (QuidelOrtho Inc, San Diego, USA), compared to central laboratory testing (CLT) in accelerated diagnostic protocols (ADP) in real time in a clinical environment.
Methods: In a nested sub-study of a pragmatic randomised control trial, consecutive patients with suspected acute coronary syndrome (ACS) and chest pain <12 h duration were randomised to the ESC 0/1 and 0/3-h ADP. Subjects underwent sampling for Quidel TriageTrue POC hs-TnI whole blood and plasma, CLT hs-TnT Roche Elecsys and a validated, NICE approved CLT High sensitivity cardiac troponin I (hs-TnI) (Siemens Attellica) at each time point.
Close Cardiovascular Monitoring during the Early Stages of Treatment for Patients Receiving Immune Checkpoint Inhibitors.
Pharmaceuticals (Basel)
July 2024
Department of Cardiology, AZ Maria Middelares, 9000 Ghent, Belgium.
There is an unmet medical need for the early detection of immune checkpoint inhibitor (ICI)-induced cardiovascular (CV) adverse events due to a lack of adequate biomarkers. This study aimed to provide insights on the incidence of troponin elevations and echocardiographic dynamics during ICI treatment in cancer patients and their role as potential biomarkers for submyocardial damage. In addition, it is the first study to compare hs-TnT and hs-TnI in ICI-treated patients and to evaluate their interchangeability in the context of screening.
View Article and Find Full Text PDFAtrial Fibrillation and Clonal Hematopoiesis in TET2 and ASXL1.
JAMA Cardiol
June 2024
Department of Medicine, Baylor College of Medicine, Houston, Texas.
Importance: Clonal hematopoiesis of indeterminate potential (CHIP) may contribute to the risk of atrial fibrillation (AF) through its association with inflammation and cardiac remodeling.
Objective: To determine whether CHIP was associated with AF, inflammatory and cardiac biomarkers, and cardiac structural changes.
Design, Setting, And Participants: This was a population-based, prospective cohort study in participants of the Atherosclerosis Risk in Communities (ARIC) study and UK Biobank (UKB) cohort.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!